Top

Published in:

01-09-2015 | Research Article

Coexpression of c-Met and Notch-1 correlates with poor prognosis in resected non-small-cell lung cancer

Authors: Ximing Wang, Na Song, Ye Zhang, Ying Cai, Yunpeng Liu, Xiujuan Qu, Zhi Li, Danni Li, Kezuo Hou, Jian Kang, Xuejun Hu

Published in: Tumor Biology | Issue 9/2015

Abstract

Despite considerable advances in chemotherapy, radiotherapy, target therapy, and biological therapy, the prognosis for those with resected non-small-cell lung cancer (NSCLC) has not substantially improved. It was recently reported that two receptors, Notch-1 and c-Met, correlate directly or indirectly with the initiation and development of malignant tumors, such as lung cancer; however, the prognostic value of coexpression of these receptors and their relationship in resected NSCLC was not clear. In this study, the expression levels of Notch-1 and c-Met in 117 patients with resected NSCLC were assessed using immunohistochemistry (IHC). The results showed that the positive expression rate of Notch-1 in total patients was 59.8 %. The positive expression rate of c-Met in the all population was 69.2 %. In addition, a significant positive association was shown between Notch-1 and c-Met (P < 0.001). Simultaneously, patients with coexpression of both receptors had a significantly poorer prognosis than those without coexpression (P < 0.001). Multivariate analysis showed that T stage (P = 0.016) and c-Met expression (P < 0.001) were independent prognostic factors. In conclusion, coexpression of both receptors correlates with poorer prognosis in patients with resected NSCLC. Targeting both receptors simultaneously may prove a more effective antitumor strategy. Patients with coexpression of both receptors might benefit from cotargeting Notch-1 and c-Met.

Matsuguma H, Nakahara R, Iqarashi S, Ishikawa Y, Suzuki H, Miyazawa N, et al. Pathologic stage I non-small cell lung cancer with high levels of preoperative serum carcinoembryonic antigen: clinicopathologic characteristics and prognosis. J Thorac Cardiovasc Surg. 2008;135(1):44–9. doi:10.1016/j.jtcvs.2007.09.032.CrossRefPubMed

Ozeki N, Fukui T, Taniguchi T, Usami N, Kawaguchi K, Ito S, et al. Significance of serum carcinoembryonic antigen level during the follow-up of patients with completely resected non-small-cell lung cancer. Eur J Cardiothorac Surg. 2014;45(4):687–92. doi:10.1093/ejcts/ezt424.CrossRefPubMed

Gumustekin M, Kargi A, Bulut G, Gozukizil A, Ulukus C, Oztop I, et al. HGF/c-Met overexpressions, but not met mutation, correlates with progression of non-small cell lung cancer. Pathol Oncol Res. 2012;18(2):209–18. doi:10.1007/s12253-011-9430-7.CrossRefPubMed

Ozasa H, Oguri T, Maeno K, Takakuwa O, Kunii E, Yagi Y, et al. Significance of c-MET overexpression in cytotoxic anticancer drug-resistant small-cell lung cancer cells. Cancer Sci. 2014;105(8):1032–9. doi:10.1111/cas.12447.CrossRefPubMedPubMedCentral

Tanaka A, Sueoka-Aragane N, Nakamura T, Takeda Y, Mitsuoka M, Yamasaki F, et al. Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients. Lung Cancer. 2012;75(1):89–94. doi:10.1016/j.lungcan.2011.06.004.CrossRefPubMed

Guo B, Cen H, Tan X, Liu W, Ke Q. Prognostic value of MET gene copy number and protein expression in patients with surgically resected non-small cell lung cancer: a meta-analysis of published literatures. PLoS One. 2014;9(6):e99399. doi:10.1371/journal.pone.0099399. eCollection 2014.CrossRefPubMedPubMedCentral

Chen G, Qiu Y, Sun L, Yu M, Wang W, Xiao W, et al. The jagged-2/notch-1/hes-1 pathway is involved in intestinal epithelium regeneration after intestinal ischemia-reperfusion injury. PLoS One. 2013;8(10):e76274. doi:10.1371/journal.pone.0076274. eCollection 2013.CrossRefPubMedPubMedCentral

Yao L, Kan EM, Kaur C, Dheen ST, Hao A, Lu J, et al. Notch-1 signaling regulates microglia activation via NF-kappa B pathway after hypoxic exposure in vivo and in vitro. PLoS One. 2013;8(11):e78439. doi:10.1371/journal.pone.0078439. eCollection 2013.CrossRefPubMedPubMedCentral

Li L, Zhao F, Lu J, Li T, Yang H, Wu C, et al. Notch-1 signaling promotes the malignant features of human breast cancer through NF-kappa B activation. PLoS One. 2014;9(4):e95912. doi:10.1371/journal.pone.0095912. eCollection 2014.CrossRefPubMedPubMedCentral

10.

Eliasz S, Liang S, Chen Y, De Marco MA, Machek O, Skucha S, et al. Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. Oncogene. 2010;29(17):2488–98. doi:10.1038/onc.2010.7.CrossRefPubMedPubMedCentral

11.

Chen Y, De Marco MA, Graziani I, Gazdar AF, Strack PR, Miele L, et al. Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung. Cancer Res. 2007;67:7954–9. doi:10.1158/0008-5472.CAN-07-1229.CrossRefPubMed

12.

Williams CK, Li JL, Murga M, Harris AL, Tosato G. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood. 2006;107(3):931–9. doi:10.1182/blood-2005-03-1000.CrossRefPubMedPubMedCentral

13.

Donnem T, Andersen S, AI-Shibli K, Al-Saad S, Busund LT, Bremnes RM. Prognostic impact of Notch ligands and receptors in non-small cell lung cancer: coexpression of Notch-1 and vascular endothelial growth factor-A predicts poor survival. Cancer. 2010;116(24):5676–85. doi:10.1002/cncr.25551.CrossRefPubMed

14.

Apostolou P, Toloudi M, Ioannou E, Kourtidou E, Chatziioannou M, Kopic A, et al. Study of the interaction among Notch pathway receptors, correlation with stemness, as well as their interaction with CD44, dipeptidyl peptidase-IV, hepatocyte growth factor receptor and the SETMAR transferase, in colon cancer stem cells. J Recept Signal Transduct Res. 2013;33(6):353–8. doi:10.3109/10799893.2013.828072.CrossRefPubMed

15.

Guessous F, Zhang Y, Kofman A, Catania A, Li Y, Schiff D, et al. microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle. 2010;9(6):1031–6.CrossRefPubMedPubMedCentral

16.

Yun J, Pannuti A, Espinoza I, Zhu H, Hicks C, Zhu X, et al. Crosstalk between PKC-alpha and Notch-4 in endocrine-resistant breast cancer cells. Oncogenesis. 2013;2:e60. doi:10.1038/oncsis.2013.26.CrossRefPubMedPubMedCentral

17.

Breindel JL, Haskins JW, Cowell EP, Zhao M, Nguyen DX, Stern DF. EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis. Cancer Res. 2013;73(16):5053–65. doi:10.1158/0008-5472.CAN-12-3775.CrossRefPubMedPubMedCentral

18.

Yang L, Li J, Ran L, Pan F, Zhao X, Ding Z, et al. Phosphorylated insulin-like growth factor 1 receptor is implicated in resistance to the cytostatic effect of gefitinib in colorectal cancer cells. J Gastrointest Surg. 2011;15(6):942–57. doi:10.1007/s11605-011-1504-z.CrossRefPubMed

19.

Kumai T, Matsuda Y, Oikawa K, Aoki N, Kimura S, Harabuchi Y, et al. EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy. Br J Cancer. 2013;109(8):2155–66. doi:10.1038/bjc.2013.577.CrossRefPubMedPubMedCentral

20.

Li H, Hu H, Wang R, Pan Y, Wang L, Li Y, et al. Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients. Onco Targets Ther. 2014;7:513–24. doi:10.2147/OTT.S60122. eCollection 2014.CrossRefPubMedPubMedCentral

21.

Farrell J, Kelly C, Rauch J, Kida K, García-Muñoz A, Monsefi N, et al. HGF induces epithelial-to-mesenchymal transition by modulating the mammalian hippo/MST2 and ISG15 pathways. J Proteome Res. 2014;13(6):2874–86. doi:10.1021/pr5000285.CrossRefPubMed

22.

Huang J, Song H, Liu B, Yu B, Wang R, Chen L. Expression of Notch-1 and its clinical significance in different histological subtypes of human lung adenocarcinoma. J Exp Clin Cancer Res : CR. 2013;32:84. doi:10.1186/1756-9966-32-84.CrossRefPubMedPubMedCentral

23.

Xie M, Zhang L, He CS, Xu F, Liu JL, Hu ZH, et al. Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells. J Cell Biochem. 2012;113(5):1501–13. doi:10.1002/jcb.24019.PubMed

24.

Stella MC, Trusolino L, Pennacchietti S, Comoglio PM. Negative feedback regulation of Met-dependent invasive growth by Notch. Mol Cell Biol. 2005;25(10):3982–96. doi:10.1128/MCB.25.10.3982-3996.2005.CrossRefPubMedPubMedCentral

Title: Coexpression of c-Met and Notch-1 correlates with poor prognosis in resected non-small-cell lung cancer
Authors: Ximing Wang
Na Song
Ye Zhang
Ying Cai
Yunpeng Liu
Xiujuan Qu
Zhi Li
Danni Li
Kezuo Hou
Jian Kang
Xuejun Hu
Publication date: 01-09-2015
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 9/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3404-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2015

Decreased expression of RPS15A suppresses proliferation of lung cancer cells

Retraction Note to: relationships between PTEN gene mutations and prognosis in glioma: a meta-analysis

Retraction Note to: Silencing of the Smad nuclear interacting protein 1 (SNIP1) by siRNA inhibits proliferation and induces apoptosis in pituitary adenoma cells

Long non-coding RNA LINC01296 is a potential prognostic biomarker in patients with colorectal cancer

miR-139-5p suppresses cancer cell migration and invasion through targeting ZEB1 and ZEB2 in GBM

Retraction Note to: Identification of core miRNA based on small RNA-seq and RNA-seq for colorectal cancer by bioinformatics

Keynote webinar | Spotlight on antibody–drug conjugates in cancer